Intralipid

Soybean oil, the active ingredient in Intralipid, is an intravenous lipid emulsion presented as a sterile emulsion for injection use. It provides calories and essential fatty acids for patients who cannot receive enteral feeding and helps prevent essential fatty acid deficiency.

GNH USA supplies Intralipid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Intralipid is used in parenteral nutrition to address energy and essential fatty acid needs in patients unable to receive enteral feeding.

- Parenteral nutrition: supplies calories and essential fatty acids for patients who cannot tolerate oral or tube feeding. - Prevention of essential fatty acid deficiency: maintains adequate levels of linoleic and alpha‑linolenic acids during prolonged intravenous therapy. - Support in high‑calorie requirements: provides additional energy for patients with increased metabolic demand such as burns or trauma.

Adverse reactions may occur with intravenous lipid emulsions and should be monitored during therapy.

Common Side Effects: - Hypertriglyceridemia: elevated serum triglyceride levels. - Fever or chills: transient temperature rise during infusion. - Infusion site reactions: erythema, pain, or swelling at the catheter site.

Serious or Rare Side Effects: - Fat overload syndrome: severe metabolic disturbance from excess lipids. - Pancreatitis: inflammation of the pancreas linked to high triglyceride levels. - Anaphylactic reaction: rare severe allergic response, potentially life‑threatening. - Pulmonary embolism: lipid particles may obstruct pulmonary vessels. - Hepatic dysfunction: abnormal liver enzyme elevations. - Thrombocytopenia: reduced platelet count.

Before initiating Intralipid therapy, clinicians should assess patient risk factors and monitor relevant laboratory parameters.

- Baseline triglyceride assessment: measure serum triglycerides to avoid excessive lipid load. - Blood glucose monitoring: watch for hyperglycemia, especially in diabetic patients. - Liver function evaluation: check hepatic enzymes periodically. - Aseptic technique: ensure sterile handling to prevent contamination. - Soy allergy screening: avoid use in patients with known hypersensitivity to soy components. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intralipid may interact with other therapies that affect lipid metabolism or coagulation.

Major Interactions (Avoid): - Concurrent lipid emulsions: may cause cumulative lipid overload. - Propofol infusion: both provide lipids, increasing risk of hypertriglyceridemia. - High‑dose heparin: can elevate serum triglycerides when combined.

Moderate Interactions (Monitor Closely): - Warfarin: lipid infusion may alter INR, requiring closer monitoring. - Glucose‑containing solutions: combined use can exacerbate hyperglycemia. - Certain antibiotics (e.g., ceftriaxone): may precipitate when mixed with lipid emulsions.